---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000035"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-11-10T21:36:23+00:00"
generated_at: "2026-11-10T21:37:05.357624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio Q1 FY2027 revenue rises to $1.1M; IBIO-600 SAD dosing complete, IBIO-610 IND due end-2026

## Summary
- Revenue of ~$1.1M vs $0.1M a year earlier; R&D $6.7M (+87% YoY) on IBIO-600 Phase 1, NHP studies and CMC; G&A $2.8M (+10%).
- Cash, cash equivalents and investments in debt securities totaled ~$76.7M as of September 30, 2026.
- IBIO-610 NHP data at EASD: fat was 93% of weight lost with semaglutide combo vs 77% for semaglutide alone; lean mass 6% vs 22%.
- IBIO-600 Phase 1 single ascending dose dosing complete; interim SAD data and start of multiple ascending dose portion expected in Q1 2027.
- iBio targets an IND-equivalent filing for IBIO-610 by end of 2026 and first-in-human studies in the first half of 2027.

## SEC filing metadata
- accession: 0001420720-26-000035
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-11-10T21:36:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/0001420720-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/ibio-20261110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000035
- JSON: https://secwatch.observer/filing/0001420720-26-000035.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.